CY2019025I1 - Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης - Google Patents

Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης

Info

Publication number
CY2019025I1
CY2019025I1 CY2019025C CY2019025C CY2019025I1 CY 2019025 I1 CY2019025 I1 CY 2019025I1 CY 2019025 C CY2019025 C CY 2019025C CY 2019025 C CY2019025 C CY 2019025C CY 2019025 I1 CY2019025 I1 CY 2019025I1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
reverse transcription
nucleoside reverse
transcription inhibitor
inhibitor
Prior art date
Application number
CY2019025C
Other languages
English (en)
Other versions
CY2019025I2 (el
Original Assignee
Merck Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2019025(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc. filed Critical Merck Canada Inc.
Publication of CY2019025I2 publication Critical patent/CY2019025I2/el
Publication of CY2019025I1 publication Critical patent/CY2019025I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
CY2019025C 2010-03-30 2019-05-16 Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης CY2019025I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US32157310P 2010-04-07 2010-04-07
EP11761856.1A EP2552902B1 (en) 2010-03-30 2011-03-28 Non-nucleoside reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
CY2019025I2 CY2019025I2 (el) 2019-11-27
CY2019025I1 true CY2019025I1 (el) 2019-11-27

Family

ID=44710363

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20171100114T CY1118774T1 (el) 2010-03-30 2017-01-25 Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
CY2019025C CY2019025I1 (el) 2010-03-30 2019-05-16 Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
CY2019026C CY2019026I1 (el) 2010-03-30 2019-05-16 Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100114T CY1118774T1 (el) 2010-03-30 2017-01-25 Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2019026C CY2019026I1 (el) 2010-03-30 2019-05-16 Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης

Country Status (44)

Country Link
US (2) US8486975B2 (el)
EP (2) EP2924034B1 (el)
JP (2) JP5281718B2 (el)
KR (1) KR101421861B1 (el)
CN (1) CN102971308B (el)
AR (1) AR080859A1 (el)
AU (1) AU2011235568B2 (el)
BR (1) BR112012024691B1 (el)
CA (1) CA2794377C (el)
CL (1) CL2012002744A1 (el)
CO (1) CO6630126A2 (el)
CR (1) CR20120503A (el)
CY (3) CY1118774T1 (el)
DK (2) DK2924034T3 (el)
DO (1) DOP2012000256A (el)
EA (1) EA024804B1 (el)
EC (1) ECSP12012201A (el)
ES (2) ES2609636T3 (el)
FI (1) FIC20190021I1 (el)
GE (1) GEP20156368B (el)
HK (2) HK1175471A1 (el)
HN (1) HN2012002039A (el)
HR (2) HRP20150427T1 (el)
HU (4) HUE025336T2 (el)
IL (2) IL222030A (el)
LT (3) LT2924034T (el)
LU (2) LUC00114I2 (el)
MA (1) MA34170B1 (el)
ME (2) ME02181B (el)
MX (1) MX2012011379A (el)
MY (1) MY163979A (el)
NI (1) NI201200146A (el)
NL (1) NL300980I2 (el)
NO (2) NO2019018I1 (el)
NZ (1) NZ602670A (el)
PE (1) PE20130158A1 (el)
PL (2) PL2924034T3 (el)
PT (2) PT2924034T (el)
RS (2) RS54017B1 (el)
SG (1) SG184347A1 (el)
SI (2) SI2552902T1 (el)
TN (1) TN2012000455A1 (el)
TW (1) TWI458719B (el)
WO (1) WO2011120133A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2924034T (pt) * 2010-03-30 2017-01-06 Merck Canada Inc Composição farmacêutica compreendendo um inibidor de transcritase reversa não nucleosídico
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
WO2014052171A1 (en) * 2012-09-26 2014-04-03 Merck Sharp & Dohme Corp. Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
WO2014089140A1 (en) 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2015077273A1 (en) * 2013-11-22 2015-05-28 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
EP3077376B1 (en) * 2013-12-04 2019-10-16 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
PT3125894T (pt) * 2014-04-01 2020-11-05 Merck Sharp & Dohme Profármacos de inibidores da transcriptase reversa do vih
HRP20211687T1 (hr) 2015-12-02 2022-03-04 Merck Sharp & Dohme Corp. Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin
US11077050B2 (en) 2017-03-24 2021-08-03 Merck Sharp & Dohme Corp. Formulation for parenteral administration
CA3060222A1 (en) 2017-04-18 2018-10-25 Cipla Limited Combination therapy for use in treating retroviral infections
CA3090652A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
WO2020018352A1 (en) 2018-07-17 2020-01-23 Merck Sharp & Dohme Corp. Hiv drug combination for increasing barrier against resistance
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
RU2344128C2 (ru) 2003-03-24 2009-01-20 Ф.Хоффманн-Ля Рош Аг Бензилпиридазиноны как ингибиторы обратной транскриптазы
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
EP1742908B1 (en) 2004-04-23 2009-11-11 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
CA2592092A1 (en) 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
WO2007045572A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
RU2010125220A (ru) * 2007-11-20 2011-12-27 Мерк Шарп Энд Домэ Корп. (Us) Ненуклеозидные ингибиторы обратной транскриптазы
PT2924034T (pt) * 2010-03-30 2017-01-06 Merck Canada Inc Composição farmacêutica compreendendo um inibidor de transcritase reversa não nucleosídico

Also Published As

Publication number Publication date
EP2552902A4 (en) 2013-09-04
DK2924034T3 (en) 2017-02-06
US8486975B2 (en) 2013-07-16
FIC20190021I1 (fi) 2019-04-17
GEP20156368B (en) 2015-09-25
RS55505B1 (sr) 2017-05-31
TWI458719B (zh) 2014-11-01
CN102971308B (zh) 2015-02-04
CA2794377C (en) 2015-06-16
JP5281718B2 (ja) 2013-09-04
EP2924034A1 (en) 2015-09-30
AR080859A1 (es) 2012-05-16
CY2019025I2 (el) 2019-11-27
BR112012024691B1 (pt) 2020-11-17
HK1175471A1 (en) 2013-07-05
CR20120503A (es) 2013-01-09
AU2011235568B2 (en) 2013-09-12
SI2924034T1 (sl) 2017-05-31
HN2012002039A (es) 2015-08-24
PL2924034T3 (pl) 2017-07-31
ES2609636T3 (es) 2017-04-21
CL2012002744A1 (es) 2012-12-14
NO2019018I1 (no) 2019-04-24
IL222030A (en) 2014-07-31
EP2552902B1 (en) 2015-03-11
TW201139409A (en) 2011-11-16
NL300980I2 (nl) 2021-06-17
PT2552902E (pt) 2015-06-02
LUC00113I2 (el) 2024-05-22
EP2924034B1 (en) 2016-11-02
LTC2552902I2 (lt) 2019-12-10
NI201200146A (es) 2013-03-18
MA34170B1 (fr) 2013-04-03
EA024804B1 (ru) 2016-10-31
KR101421861B1 (ko) 2014-07-22
CN102971308A (zh) 2013-03-13
DK2552902T3 (en) 2015-06-15
HK1209121A1 (en) 2016-03-24
NZ602670A (en) 2014-09-26
CY2019026I2 (el) 2020-05-29
RS54017B1 (en) 2015-10-30
ME02181B (me) 2015-10-20
CY2019026I1 (el) 2020-05-29
SI2552902T1 (sl) 2015-10-30
EP2552902A1 (en) 2013-02-06
AU2011235568A1 (en) 2012-11-01
CY1118774T1 (el) 2017-07-12
HUS1900021I1 (hu) 2019-05-28
IL233334A (en) 2015-09-24
PE20130158A1 (es) 2013-02-28
JP2013510800A (ja) 2013-03-28
JP2013209405A (ja) 2013-10-10
HRP20150427T1 (hr) 2015-07-03
MX2012011379A (es) 2012-11-30
JP5886790B2 (ja) 2016-03-16
LT2924034T (lt) 2016-12-27
LTPA2019506I1 (lt) 2019-04-25
HRP20161680T1 (hr) 2017-01-27
ME02570B (me) 2017-06-20
NO2019019I1 (no) 2019-04-24
LTPA2019507I1 (lt) 2019-04-25
EA201290976A1 (ru) 2013-03-29
PL2552902T3 (pl) 2015-10-30
IL233334A0 (en) 2014-09-01
NL300980I1 (nl) 2019-04-24
ES2536295T3 (es) 2015-05-22
CO6630126A2 (es) 2013-03-01
HUE031785T2 (en) 2017-08-28
SG184347A1 (en) 2012-11-29
PT2924034T (pt) 2017-01-06
LUC00113I9 (el) 2024-06-07
US20130296382A1 (en) 2013-11-07
LUC00114I2 (el) 2020-07-10
MY163979A (en) 2017-11-15
HUS1900022I1 (hu) 2019-05-28
LTC2924034I2 (lt) 2020-10-12
CA2794377A1 (en) 2011-10-06
DOP2012000256A (es) 2012-12-15
ECSP12012201A (es) 2012-10-30
LUC00114I1 (el) 2019-04-17
HUE025336T2 (en) 2016-03-29
KR20120128703A (ko) 2012-11-27
US20110245296A1 (en) 2011-10-06
TN2012000455A1 (en) 2014-01-30
BR112012024691A2 (pt) 2019-07-02
WO2011120133A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
CY2019025I1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
SMT201700008B (it) Composizione farmaceutica
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
DK3178818T3 (da) Pyrazolylquinoxalinkinasehæmmere
DK3097925T3 (da) Farmaceutisk sammensætning
DK3246018T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
BRPI1015939A2 (pt) composição farmacêutica
DK4159205T3 (da) Hidtil ukendt farmaceutisk sammensætning
BR112013013571A2 (pt) comprimido para a desintegração oral
EE201300005A (et) Ravimkoostis
NL301214I2 (nl) Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
CO6801722A2 (es) Composiciones farmacéuticas
BR112012003149A2 (pt) composição farmacêutica
DOP2011000242A (es) Macrolido anti-inflamatorio
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
FR2961401B1 (fr) Composition anti-inflammatoire
BR112012029887A2 (pt) composição farmacêutica
DK2564056T3 (da) Turbine
FI20105327A (fi) Farmaseuttinen koostumus
BRPI1009131A2 (pt) composição farmacêutica compreendendo aliscireno
ES1073868Y (es) Turbina chaves-2
TH106773B (th) 4-ไตรเมธิลแอมโมนิโอ-บิวไทเรทในฐานะสารยับยั้ง cpt2
CN301140175S (zh) 标贴
DOP2009000016A (es) Composicion farmaceutica